نتایج جستجو برای: terminal msp1

تعداد نتایج: 149666  

2013
Kae Pusic Danielle Clements Sophie Kobuch George Hui

The P. falciparum Merozoite Surface Protein 1-42 (MSP1-42) is one of the most studied malaria subunit vaccine candidates. The N-terminal fragment of MSP1-42, MSP1-33, is primarily composed of allelic sequences, and has been shown to possess T helper epitopes that influence protective antibody responses toward the C-terminal region, MSP1-19. A truncated MSP1-42 vaccine, Construct 33-I, consistin...

2011
Kae M. Pusic Caryn N. Hashimoto Axel Lehrer Charmaine Aniya David E. Clements George S. Hui

The C-terminal 42 kDa fragments of the P. falciparum Merozoite Surface Protein 1, MSP1-42 is a leading malaria vaccine candidate. MSP1-33, the N-terminal processed fragment of MSP1-42, is rich in T cell epitopes and it is hypothesized that they enhance antibody response toward MSP1-19. Here, we gave in vivo evidence that T cell epitope regions of MSP1-33 provide functional help in inducing anti...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه پیام نور - دانشگاه پیام نور استان تهران - دانشکده علوم پایه 1391

مالاریا یکی از بیماری های مهم انگلی در کشورهای گرمسیری دنیا است. پلاسمودیوم فالسیپاروم انگل تک یاخته ای است که تب سه یک بدخیم را ایجاد می کند. آنتی ژن های پلاسمودیوم فالسیپاروم در سطح انگل یا در سطح سلول های آلوده ،کاندیداهای عمده جهت تولید واکسن می باشند، مانند: msp 1 و msp2 . کربوهیدرات های متصل به پروتئین های انگل مالاریا بعنوان اپی توپ های آنتی ژنیک مطرح بوده و بوسیله سیستم ایمنی میزبان تشخ...

Journal: :Infection and immunity 2004
Armead H Johnson Rose G F Leke Nancy R Mendell Dewon Shon Young Ju Suh Dennis Bomba-Nkolo Viviane Tchinda Samuel Kouontchou Lucy W Thuita Anne Marie van der Wel Alan Thomas Anthony Stowers Allan Saul Ainong Zhou Diane W Taylor Isabella A Quakyi

The apical membrane antigen 1 (AMA1), merozoite surface antigen 2 (MSA2), and merozoite surface protein 1 (MSP1) are asexual-stage proteins currently being evaluated for inclusion in a vaccine for Plasmodium falciparum. Accordingly, it is important to understand factors that control antibody responses to these antigens. Antibody levels in plasma from residents of Etoa, Cameroon, between the age...

Journal: :PLoS Clinical Trials 2007
Elissa Malkin Carole A Long Anthony W Stowers Lanling Zou Sanjay Singh Nicholas J MacDonald David L Narum Aaron P Miles Andrew C Orcutt Olga Muratova Samuel E Moretz Hong Zhou Ababacar Diouf Michael Fay Eveline Tierney Philip Leese Siddhartha Mahanty Louis H Miller Allan Saul Laura B Martin

OBJECTIVES To assess the safety and immunogenicity of two vaccines, MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, targeting blood-stage Plasmodium falciparum parasites. DESIGN A Phase 1 open-label, dose-escalating study. SETTING Quintiles Phase 1 Services, Lenexa, Kansas between July 2004 and November 2005. PARTICIPANTS Sixty healthy malaria-naïve volunteers 18-48 y of age. INTER...

Journal: :Infection and immunity 2003
Sanjay Singh Michael C Kennedy Carole A Long Allan J Saul Louis H Miller Anthony W Stowers

Protection against Plasmodium falciparum can be induced by vaccination in animal models with merozoite surface protein 1 (MSP1), which makes this protein an attractive vaccine candidate for malaria. In an attempt to produce a product that is easily scaleable and inexpensive, we expressed the C-terminal 42 kDa of MSP1 (MSP1(42)) in Escherichia coli, refolded the protein to its native form from i...

Journal: :Infection and immunity 1997
J H Tian S Kumar D C Kaslow L H Miller

Vaccination with native full-length merozoite surface protein 1 (MSP1) or with recombinant C-terminal peptides protects mice against lethal challenge with virulent malaria parasites. To determine whether other regions of MSP1 can also induce protection, Plasmodium yoelii MSP1 was divided into four separate regions. Each was expressed in Escherichia coli as a fusion protein with glutathione S-tr...

Journal: :PLoS ONE 2008
Anton R. Dluzewski Irene T. Ling John M. Hopkins Munira Grainger Gabriele Margos Graham H. Mitchell Anthony A. Holder Lawrence H. Bannister

Plasmodium falciparum Merozoite Surface Protein 1 (MSP1) is synthesized during schizogony as a 195-kDa precursor that is processed into four fragments on the parasite surface. Following a second proteolytic cleavage during merozoite invasion of the red blood cell, most of the protein is shed from the surface except for the C-terminal 19-kDa fragment (MSP1(19)), which is still attached to the me...

Journal: :Infection and immunity 2012
David K Moss Edmond J Remarque Bart W Faber David R Cavanagh David E Arnot Alan W Thomas Anthony A Holder

Merozoite surface protein 1 (MSP1) is a target for malaria vaccine development. Antibodies to the 19-kDa carboxy-terminal region referred to as MSP1(19) inhibit erythrocyte invasion and parasite growth, with some MSP1-specific antibodies shown to inhibit the proteolytic processing of MSP1 that occurs at invasion. We investigated a series of antibodies purified from rabbits immunized with MSP1(1...

2011
Danny W. Wilson Freya J. I. Fowkes Paul R. Gilson Salenna R. Elliott Livingstone Tavul Pascal Michon Elija Dabod Peter M. Siba Ivo Mueller Brendan S. Crabb James G. Beeson

BACKGROUND Antibodies targeting blood stage antigens are important in protection against malaria, but the key targets and mechanisms of immunity are not well understood. Merozoite surface protein 1 (MSP1) is an abundant and essential protein. The C-terminal 19 kDa region (MSP1-19) is regarded as a promising vaccine candidate and may also be an important target of immunity. METHODOLOGY/FINDING...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید